The success of Moderna in Phase 3 trials, based on the internal study of trial data, comes days after Pfizer declared a similar effectiveness rate of its vaccine candidate being developed in coordination with Germany's BioNtech. Their candidate was found to be 90 percent effective, and is expected to receive EUA from the American regulator by November-end.
 _(The above story first appeared on LatestLY on Nov 16, 2020 05:50 PM IST. For more news and updates on politics, world, sports, entertainment and lifestyle, log on to our websitelatestly.com)._


--DocBreak--
Be lazy, save lives,' young Germans urged in comic COVID video


--DocBreak--
"We look forward to the next milestones of submitting for an EUA in the US, and regulatory filings in countries around the world, while we continue to collect data on the safety and efficacy of the vaccine in the COVE study. We remain committed to and focused on doing our part to help end the COVID-19 pandemic," the Moderna CEO added.


--DocBreak--
Moderna, in the preliminary analysis of its trial data, found a broadly consistent safety and efficacy profile across all evaluated subgroups. As more cases accrue leading up to the final analysis, the company expects the point estimate for vaccine efficacy may change. The final set of data from the full phase study would be submitted to a peer-reviewed publication.

